JP2022500472A5 - - Google Patents

Info

Publication number
JP2022500472A5
JP2022500472A5 JP2021515045A JP2021515045A JP2022500472A5 JP 2022500472 A5 JP2022500472 A5 JP 2022500472A5 JP 2021515045 A JP2021515045 A JP 2021515045A JP 2021515045 A JP2021515045 A JP 2021515045A JP 2022500472 A5 JP2022500472 A5 JP 2022500472A5
Authority
JP
Japan
Prior art keywords
methyl
acetamide
oxy
alkyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021515045A
Other languages
English (en)
Japanese (ja)
Other versions
JP7606960B2 (ja
JP2022500472A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/051661 external-priority patent/WO2020061150A1/en
Publication of JP2022500472A publication Critical patent/JP2022500472A/ja
Publication of JP2022500472A5 publication Critical patent/JP2022500472A5/ja
Priority to JP2024168726A priority Critical patent/JP2025011144A/ja
Application granted granted Critical
Publication of JP7606960B2 publication Critical patent/JP7606960B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021515045A 2018-09-19 2019-09-18 O-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グルコピラノシダーゼ阻害剤 Active JP7606960B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024168726A JP2025011144A (ja) 2018-09-19 2024-09-27 O-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グルコピラノシダーゼ阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862733484P 2018-09-19 2018-09-19
US62/733,484 2018-09-19
US201862750000P 2018-10-24 2018-10-24
US62/750,000 2018-10-24
PCT/US2019/051661 WO2020061150A1 (en) 2018-09-19 2019-09-18 O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024168726A Division JP2025011144A (ja) 2018-09-19 2024-09-27 O-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グルコピラノシダーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2022500472A JP2022500472A (ja) 2022-01-04
JP2022500472A5 true JP2022500472A5 (cg-RX-API-DMAC7.html) 2022-09-26
JP7606960B2 JP7606960B2 (ja) 2024-12-26

Family

ID=68073263

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021515045A Active JP7606960B2 (ja) 2018-09-19 2019-09-18 O-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グルコピラノシダーゼ阻害剤
JP2024168726A Pending JP2025011144A (ja) 2018-09-19 2024-09-27 O-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グルコピラノシダーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024168726A Pending JP2025011144A (ja) 2018-09-19 2024-09-27 O-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グルコピラノシダーゼ阻害剤

Country Status (22)

Country Link
US (2) US12180205B2 (cg-RX-API-DMAC7.html)
EP (1) EP3853226A1 (cg-RX-API-DMAC7.html)
JP (2) JP7606960B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210060513A (cg-RX-API-DMAC7.html)
CN (2) CN113166137B (cg-RX-API-DMAC7.html)
AU (1) AU2019344922B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004739A2 (cg-RX-API-DMAC7.html)
CA (1) CA3113009A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000646A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021004873A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210181A (cg-RX-API-DMAC7.html)
IL (2) IL315564A (cg-RX-API-DMAC7.html)
JO (1) JOP20210036A1 (cg-RX-API-DMAC7.html)
MA (1) MA53648A (cg-RX-API-DMAC7.html)
MX (1) MX2021003232A (cg-RX-API-DMAC7.html)
PE (1) PE20211591A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550439A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102379XA (cg-RX-API-DMAC7.html)
TW (1) TWI863926B (cg-RX-API-DMAC7.html)
UA (1) UA130690C2 (cg-RX-API-DMAC7.html)
UY (1) UY38376A (cg-RX-API-DMAC7.html)
WO (1) WO2020061150A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166137B (zh) 2018-09-19 2024-08-16 比奥根Ma公司 O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
AR123132A1 (es) * 2020-08-03 2022-11-02 Biogen Ma Inc Formas cristalinas de un inhibidor de la o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
KR102533471B1 (ko) 2020-11-23 2023-05-19 (주) 메디프론디비티 O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도
WO2025184490A1 (en) 2024-03-01 2025-09-04 Biogen Ma Inc. N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease
WO2026112144A1 (en) 2024-11-20 2026-05-28 Dewpoint Therapeutics, Inc. Modulators of beta catenin and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP2004520347A (ja) 2001-01-15 2004-07-08 グラクソ グループ リミテッド Ldl−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
EP2569302A1 (en) 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013170072A2 (en) 2012-05-09 2013-11-14 Neurop, Inc. Compounds for the treatment of neurological disorders
EP2914604A4 (en) 2012-10-31 2016-07-20 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
PL2953941T3 (pl) 2013-02-11 2017-11-30 Constellation Pharmaceuticals, Inc. Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania
WO2014159234A1 (en) * 2013-03-14 2014-10-02 Merck Patent Gmbh Glycosidase inhibitors
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
KR20160100407A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
CN105753814A (zh) 2015-01-01 2016-07-13 成都贝斯凯瑞生物科技有限公司 取代氮杂环衍生物及其应用
EP3555087A1 (en) * 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Monocyclic oga inhibitor compounds
EP3555094A1 (en) 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Bicyclic oga inhibitor compounds
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5-甲基-1,2,4-二唑-3-基化合物
EP3765458B1 (en) * 2018-03-14 2023-01-11 Biogen MA Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
US11459324B2 (en) 2018-03-14 2022-10-04 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors
WO2019243531A1 (en) 2018-06-20 2019-12-26 Janssen Pharmaceutica Nv Oga inhibitor compounds
CN113166137B (zh) 2018-09-19 2024-08-16 比奥根Ma公司 O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂

Similar Documents

Publication Publication Date Title
JP2021518340A5 (cg-RX-API-DMAC7.html)
JP2014503528A5 (cg-RX-API-DMAC7.html)
US10329274B2 (en) Indole carboxamide compounds
US10071988B2 (en) Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
CA2593264A1 (en) Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP2019506430A5 (cg-RX-API-DMAC7.html)
TW201609706A (zh) 胺基嘧啶基化合物
AU2003295396B2 (en) Heteroaryl-pyramidine derivatives as JAK inhibitors
AR066120A1 (es) Derivados de pirimidinona y sus metodos de uso
EP2612854A1 (en) Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors
WO2012080729A4 (en) Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies
JP2019510006A5 (cg-RX-API-DMAC7.html)
RU2008110949A (ru) Соединения и композиции-иммуносупрессанты
RU2015120556A (ru) Ингибиторы гликозидаз и их применения
IL300298A (en) Apol1 inhibitors and methods of using the same
JP2014506599A5 (cg-RX-API-DMAC7.html)
SI3102573T1 (en) SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7
IL276575B2 (en) Inhibitors of btk and mutants thereof
JP2020517595A (ja) サイクリン依存性キナーゼcdk9の新規阻害剤
JP2024517678A5 (cg-RX-API-DMAC7.html)
JP2015516429A5 (cg-RX-API-DMAC7.html)
JP2022548250A5 (cg-RX-API-DMAC7.html)
FR2943669A1 (fr) Derives de nicotinamide,leur preparation et leur application en therapeutique
JP2022504650A5 (cg-RX-API-DMAC7.html)
JP2024540318A5 (cg-RX-API-DMAC7.html)